Monitoring of tinzaparin treatment at treatment dose of 10 days in elderly patients;Surveillance d'un traitement par la tinzaparine à dose curative pendant dix jours chez le sujet âgé

Revue de Medecine Interne

Volumn 22, Issue 2, 2001, Pages 120-126

  Pautas, E ^a   Siguret, V ^a   D'Urso, M ^b   Laurent, M ^a   Gaussem, P ^a   Fevrier M ^b   Durand Gasselin, B ^b  

^a HÔPITAL CHARLES FOIX   (France)

^b Hopital Notre Dame de Bonne Secours   (France)

Author keywords

Elderly; Low molecular weight heparin; Pharmacokinetics; Tinzaparin

Indexed keywords

ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN;

AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GERIATRIC PATIENT; HUMAN; MALE; PATIENT MONITORING; PROSPECTIVE STUDY; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0035125820     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0248-8663(00)00301-5     Document Type: Article

References (18)

1. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study
2. The epidemiology of diagnosed pulmonary embolism and deep vein thrombosis in the elderly
3. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: A meta-analysis
4. Treatment of deep venous thrombosis with low-molecular-weight heparins
5. Low molecular weight heparins: Practical considerations
6. Low molecular weight heparin in the treatment of patients with venous thromboembolism
7. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis
8. A comparison of low-molecular-weight heparin for acute pulmonary embolism
9. Aging and venous thromboembolism influence the pharmocodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (Nadroparin®)
10. Prediction of creatinine clearance from serum creatinine
11. Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238)
12. Clinical pharmacokinetic considerations in the elderly: An update
13. Heparin pharmacokinetics and pharmacodynamics
14. Aging and heparin-related bleeding
15. Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers
16. Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins
17. Chemical and biological heterogeneity in low molecular weight heparins: Implications for clinical use and standardization
18. Determination of the molecular-weight distribution of low-molecularweight heparins using high-performance gel permeation chromatography